Rolling Review and Biologics

Rolling review permits a regulator to assess available sections of a biologics application as they are completed, rather than waiting for the entire submission. It is especially relevant to vaccines, monoclonal antibodies, recombinant proteins, and other complex biological medicines, where manufacturing consistency and clinical evidence require detailed evaluation.

A rolling review is a review process, not itself a marketing authorization. The regulator must still determine that the product meets applicable standards of quality, safety, and efficacy before granting permission to market it.

In India, CDSCO regulates biologics, including vaccines and recombinant-DNA products, and its functions include clinical-trial approval, marketing authorization, and post-approval changes.

CDSCO+1

Indian Regulatory Framework

The Drugs and Cosmetics Act, 1940, the New Drugs and Clinical Trials Rules, 2019, and CDSCO guidelines govern the approval and monitoring of biologics. CDSCO also provides for post-approval changes, which may require supporting data and regulatory review.

CDSCO+1

For similar biologics, India’s 2025 guideline revision emphasizes stronger analytical evidence and a stepwise demonstration of similarity. The draft was published for stakeholder comments in May 2025; its legal status should be checked against the final notified guidance applicable to the particular product.

CDSCO+1

Important Case Laws

1. Roche Products (India) Pvt. Ltd. v. Drugs Controller General of India, Delhi High Court, 25 April 2016

The Court examined approval of biosimilar versions of trastuzumab. It stressed that biosimilars cannot be treated as ordinary generic drugs because biological products are complex and cannot be assumed identical merely from the same active substance. The judgment emphasized strict compliance with the applicable biosimilar evaluation framework and adequate evidence of safety, efficacy, and similarity. It is a significant authority on rigorous regulatory scrutiny of biologics.

Indian Kanoon+1

2. Reliance Life Sciences Pvt. Ltd. v. Genentech Inc., Delhi High Court, 18 September 2019

The Court considered disputes involving a biosimilar product and regulatory approval. The decision discussed the role of CDSCO and expert committees in assessing comparability, safety, and efficacy. It illustrates that regulatory approval is grounded in scientific assessment and that legal challenges must be considered within the applicable statutory and procedural framework.

Indian Kanoon

3. Roche Products (India) Pvt. Ltd. v. Cadila Healthcare Ltd., Delhi High Court, 24 February 2020

The Court addressed whether third parties could bring civil proceedings challenging biosimilar approvals. It held that such suits were maintainable in the circumstances, explaining that the statutory appeal mechanism was not necessarily available to third parties. The case highlights the importance of procedural remedies and judicial oversight in regulatory approval disputes.

Cornelia – Judgment

Legal Principles

Rolling review of biologics should follow these principles:

Sequential scientific scrutiny: Each submitted data module may be reviewed as it becomes available, but incomplete evidence cannot be treated as conclusive proof of safety and efficacy.

Quality and manufacturing consistency: Biologics require careful evaluation of identity, purity, potency, stability, and manufacturing controls.

Conditional authorization: Any conditional or accelerated pathway must remain subject to its stated limits, required evidence, and continuing monitoring.

Post-approval responsibility: New safety information or manufacturing changes may require regulatory notification, further assessment, revised labelling, or other action.

Conclusion

Rolling review can accelerate the assessment of biologics by allowing regulators to examine completed data sections progressively. However, it does not reduce the legal standard for marketing authorization. Indian case law, particularly the Roche biosimilar litigation, underscores the need for rigorous scientific evidence, compliance with regulatory requirements, and effective judicial oversight. The central legal objective is to balance timely access to biological medicines with patient safety, product quality, and public confidence.